title: Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.
abstract: OBJECTIVE
  Type 1 diabetic subjects are at increased risk of cardiovascular disease and exhibit multiple qualitative abnormalities of apolipoprotein (apo) B100-containing lipoproteins. This stable isotope kinetic experiment was designed to study whether these abnormalities are associated with changes in the synthesis and fractional catabolic rates of VLDL-, IDL- and LDL-apoB100.
  
  
  METHODS
  Using a bolus followed by a 16-h constant infusion of 13C-leucine, we performed a kinetic study in eight men with type 1 diabetes treated with a continuous subcutaneous insulin infusion administered by an external pump and in seven healthy men, in the fed state.
  
  
  RESULTS
  The mean HbA1c level in the type 1 diabetic patients was 8.00+/-1.48%. Plasma triglyceride, and total, LDL and HDL cholesterol levels were similar in patients and control subjects. VLDL were less triglyceride rich in type 1 diabetic patients than in control subjects (VLDL triglyceride : apoB 6.91+/-0.81 vs 8.29+/-1.24 mmol/g, p=0.05). Conversely, the IDL and LDL of the type 1 diabetic patients contained relatively higher levels of triglycerides (IDL triglycerides : apoB 2.16+/-0.36 vs 1.57+/-0.30 mmol/g, p<0.01; LDL triglycerides : apoB 0.27+/-0.06 vs 0.16+/-0.04 mmol/g, p<0.05). The apoB100 pool size, production and fractional catabolic rates in the two groups of subjects were similar for all lipoprotein fractions.
  
  
  CONCLUSIONS
  Despite qualitative abnormalities, especially abnormalities of triglyceride content, the metabolism of apoB100-containing lipoproteins is not altered in type 1 diabetic men with fair glycaemic control with continuous subcutaneous insulin infusion. The high risk of atherosclerosis in these patients cannot be explained by kinetic abnormalities of apoB100-containing lipoproteins.
authors.affiliation: INSERM U498, Bocage Hospital, BP 77908, 21079, Dijon Cédex, France. laurence.duvillard@chu-dijon.fr
authors.forename: L
authors.initials: L
authors.lastname: Duvillard
authors.forename: E
authors.initials: E
authors.lastname: Florentin
authors.forename: M L
authors.initials: ML
authors.lastname: Lalanne-Mistrich
authors.forename: J M
authors.initials: JM
authors.lastname: Petit
authors.forename: S
authors.initials: S
authors.lastname: Baillot-Rudoni
authors.forename: A
authors.initials: A
authors.lastname: Brun-Pacaud
authors.forename: J M
authors.initials: JM
authors.lastname: Brun
authors.forename: P
authors.initials: P
authors.lastname: Gambert
authors.forename: B
authors.initials: B
authors.lastname: Vergès
mesh_terms: D000328:Adult; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000097:blood* / Q000302:isolation & purification; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood; D008297:Male; D012016:Reference Values
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D008055:Lipids